Over the years, China has increasingly become the hotbed and destination for the clinical research. From one side, increasingly global pharmaceutical companies have recognized the importance and advantages to integrate China into the global early and late phase clinical development but also meanwhile the china clinical research markets are further driven and facilitated by the rapidly transforming China Local R&D Innovation.

A part of our highly successful Clinical Trials series, the event, which attracts over 150 attendees, will build upon CTLCS 2017 and examine partnerships and outsourcing strategies; key regulatory changes and the effects these have had on china market access; best practice techniques in clinical operations; Data Integrity, Quality & Risk Management; and also address the need to adopt Innovative Technology to ensure safety, transparency and quality as well as the hurdles of Oncology Drug Development ,Biologics & Biosimilar so as to keep up to date with the pace of growth in the region and maintain the clinical trials boom in Asia.